Alliance Pharma PLC Grant of Options to Directors (0422A)

TIDMAPH

RNS Number : 0422A

Alliance Pharma PLC

24 September 2020

 
 For immediate release   24 September 2020 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Grant of Options to Directors

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Board has issued options over an aggregate of 655,597 ordinary shares of 1 pence each in the Company, on the recommendation of the Company's Remuneration Committee, to the PDMRs detailed below.

Peter Butterfield, Chief Executive Officer, has been awarded 165,500 unapproved share options under the Company's 2015 Share Option Plan; and, 246,269 share options have been granted pursuant to the Company's Long-Term Incentive Plan 2019.

Andrew Franklin, Chief Financial Officer, has been awarded 110,000 unapproved share options under the Company's 2015 Share Option Plan; and, 134,328 share options have been granted pursuant to the Company's Long-Term Incentive Plan 2019.

The share options awarded under the 2015 Company Share Option Plan have all been granted with an exercise price of 73.7p, being the closing mid-market price on 22(nd) September 2020, and become exercisable on 23(rd) September 2023, being the third anniversary of the date of the grant. The awards granted under the 2019 Long Term Incentive Plan have been granted at nil-cost and also become exercisable on 23(rd) September 2023.

The vesting of these awards is a subject to continued employment and the satisfaction of performance conditions based on EPS and TSR targets.

The net effect of the grant of Share Options and the resultant option holdings are shown in the table below:

 
 Name                 Share Options granted   Total no. of options 
                                               over ordinary shares 
                                               now held 
 Peter Butterfield    411,269                 3,200,453 
                     ----------------------  ---------------------- 
 Andrew Franklin      244,328                 1,853,511 
                     ----------------------  ---------------------- 
 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by person discharging managerial responsibilities.

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                         Mr Peter Butterfield 
      ---------------------------  --------------------------------------------------- 
 2     Reason for the notification 
      -------------------------------------------------------------------------------- 
 a)    Position/status              Chief Executive Officer - PDMR 
      ---------------------------  --------------------------------------------------- 
 b)    Initial notification         Initial Notification 
        /Amendment 
      ---------------------------  --------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------------------- 
 a)    Name                         Alliance Pharma plc 
      ---------------------------  --------------------------------------------------- 
 b)    Legal Entity                 N/A 
        Identifier 
      ---------------------------  --------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      -------------------------------------------------------------------------------- 
 a)    Description                  Ordinary shares of 1.0 pence each 
        of the financial             ISIN: GB0031030819 
        instrument, 
        type of instrument 
        Identification 
        code 
      ---------------------------  --------------------------------------------------- 
 b)    Nature of the                Grant of Options 
        transaction 
      ---------------------------  --------------------------------------------------- 
 c)    Currency                     GBP 
      ---------------------------  --------------------------------------------------- 
 d)    Price(s) and                    Exercise Price         No. of share options 
        volume(s)                            (p) 
      ---------------------------  ---------------------  ---------------------------- 
                                           73.7p                     165,000 
 --------------------------------  ---------------------  ---------------------------- 
                                            Nil                      246,269 
                                   ---------------------  ---------------------------- 
 
 e)    Aggregated                    Grant of 165,000 options to acquire shares 
        information                   at GBP0.737 per share at an aggregate exercise 
        - Aggregated                  value of GBP121,605. 
        volume                        Grant of 246,269 options to acquire ordinary 
        - Price                       shares of 1 pence each at nil-cost. 
        - Aggregated 
        total 
      ---------------------------  --------------------------------------------------- 
 f)    Date of the                  23 September 2020 
        transaction 
      ---------------------------  --------------------------------------------------- 
 g)    Place of the                 Outside of trading venue 
        transaction 
      ---------------------------  --------------------------------------------------- 
 
 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                         Mr Andrew Franklin 
      ---------------------------  --------------------------------------------------- 
 2     Reason for the notification 
      -------------------------------------------------------------------------------- 
 a)    Position/status              Chief Financial Officer - PDMR 
      ---------------------------  --------------------------------------------------- 
 b)    Initial notification         Initial Notification 
        /Amendment 
      ---------------------------  --------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------------------- 
 a)    Name                         Alliance Pharma plc 
      ---------------------------  --------------------------------------------------- 
 b)    Legal Entity                 N/A 
        Identifier 
      ---------------------------  --------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      -------------------------------------------------------------------------------- 
 a)    Description                  Ordinary shares of 1.0 pence each 
        of the financial             ISIN: GB0031030819 
        instrument, 
        type of instrument 
        Identification 
        code 
      ---------------------------  --------------------------------------------------- 
 b)    Nature of the                Grant of Options 
        transaction 
      ---------------------------  --------------------------------------------------- 
 c)    Currency                     GBP 
      ---------------------------  --------------------------------------------------- 
 d)    Price(s) and                    Exercise Price         No. of share options 
        volume(s)                            (p) 
      ---------------------------  ---------------------  ---------------------------- 
                                           73.7p                     110,000 
 --------------------------------  ---------------------  ---------------------------- 
                                            Nil                      134,328 
                                   ---------------------  ---------------------------- 
 
 e)    Aggregated                    Grant of 110,000 options to acquire shares 
        information                   at GBP0.737 per share at an aggregate exercise 
        - Aggregated                  value of GBP81,070. 
        volume                        Grant of 134,328 options to acquire ordinary 
        - Price                       shares of 1 pence each at nil-cost. 
        - Aggregated 
        total 
      ---------------------------  --------------------------------------------------- 
 f)    Date of the                  23 September 2020 
        transaction 
      ---------------------------  --------------------------------------------------- 
 g)    Place of the                 Outside of trading venue 
        transaction 
      ---------------------------  --------------------------------------------------- 
 

For further information:

 
 Alliance Pharma plc                          + 44 (0)1249 466966 
 Peter Butterfield, Chief Executive 
  Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk 
 Buchanan                                    + 44 (0)20 7466 5000 
 Mark Court / Hannah Ratcliff 
 
 Numis Securities Limited                    + 44 (0)20 7260 1000 
 Nominated Adviser: Freddie Barnfield 
  / Huw Jeremy 
 Corporate Broking: James Black 
 
 
 Investec Bank plc                    + 44 (0) 20 7597 5970 
 Corporate Finance: Daniel Adams / 
  Ed Thomas 
 Corporate Broking: Patrick Robb / 
  Tejas Padalkar 
 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHPPUPABUPUGGC

(END) Dow Jones Newswires

September 24, 2020 07:54 ET (11:54 GMT)